Among the various oncogenic drivers in patients with non-small cell lung cancer (NSCLC), rearrangements in the anaplastic lymphoma kinase (ALK) gene are considered to be potent drivers, presented in approximately 5% of cases, second only to epidermal growth factor receptor (EGFR) mutations (5, 6). Here, ALK is linked to non-small cell lung carcinoma.